Earnings

Dianthus Therapeutics Q3 EPS $(0.81) Beats $(0.97) Estimate, Sales $1.210M vs $396K YoY

Nov 4, 2026 · 04:25 PM ET· updated 1h ago

Dianthus Therapeutics (NASDAQ:DNTH) reported quarterly losses of $(0.81) per share which beat the analyst consensus estimate of $(0.97) by 16.49 percent. This is a 16.49 percent increase over losses of $(0.97) per share

Why It Matters

Dianthus lost less money than people thought it would this quarter. The company also grew sales a lot, which shows its business is moving forward.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

DNTH85.80

+3.10 (+3.75%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.